Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Melanoma 783Carcinoma, Non-Small-Cell Lung 170Skin Neoplasms 154Neoplasms 106Neoplasm Metastasis 100Colorectal Neoplasms 97Carcinoma, Renal Cell 95Uveal Melanoma 92Breast Neoplasms 88Squamous Cell Carcinoma of Head and Neck 85Carcinoma, Basal Cell 83Lung Neoplasms 81Ovarian Neoplasms 79Sarcoma 67Lymphoma, T-Cell, Cutaneous 66Carcinoma, Merkel Cell 66Stomach Neoplasms 58Pancreatic Neoplasms 58Head and Neck Neoplasms 55Carcinoma, Hepatocellular 53Uterine Cervical Neoplasms 52Urinary Bladder Neoplasms 50Esophageal Neoplasms 44Prostatic Neoplasms 43Triple Negative Breast Neoplasms 42Endometrial Neoplasms 41Carcinoma, Squamous Cell 39Brain Neoplasms 39Carcinoma, Transitional Cell 37Lymphoma 35

Interventions

pembrolizumab 1omega-N-Methylarginine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DNA Repair-Deficiency Disorders × Dermatologic × 1 year × Clear all
NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Completed
12 enrolled 15 charts
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡